Home › Compare › BPTS vs STAG

BPTS vs STAG: Dividend Comparison 2026

BPTS yields 24.33% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BPTS wins by $76.6K in total portfolio value
10 years
BPTS
BPTS
● Live price
24.33%
Share price
$8.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$94.9K
Annual income
$10,445.94
Full BPTS calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.06
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.70
Full STAG calculator →

Portfolio growth — BPTS vs STAG

📍 BPTS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPTSSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPTS + STAG cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BPTS pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPTS
Annual income on $10K today (after 15% tax)
$2,068.13/yr
After 10yr DRIP, annual income (after tax)
$8,879.05/yr
STAG
Annual income on $10K today (after 15% tax)
$292.69/yr
After 10yr DRIP, annual income (after tax)
$393.29/yr
At 15% tax rate, BPTS beats the other by $8,485.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPTS + STAG for your $10,000?

BPTS: 50%STAG: 50%
100% STAG50/50100% BPTS
Portfolio after 10yr
$56.6K
Annual income
$5,454.32/yr
Blended yield
9.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

BPTS
Analyst Ratings
1
Buy
Consensus: Buy
Price Target
$15.00
+82.5% upside vs current
Range: $15.00 — $15.00
Altman Z
-13.4
Piotroski
2/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.8% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPTS buys
0
STAG buys
0
No recent congressional trades found for BPTS or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPTSSTAG
Forward yield24.33% ✓3.44%
Annual dividend / share$2.00 ✓$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3% ✓
Portfolio after 10y$94.9K ✓$18.3K
Annual income after 10y$10,445.94 ✓$462.70
Total dividends collected$59.3K ✓$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$15.00$45.00 ✓

Year-by-year: BPTS vs STAG ($10,000, DRIP)

YearBPTS PortfolioBPTS Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$13,133$2,433.09$10,665$345.38+$2.5K → BPTS
2$17,039$2,986.35$11,365$358.01+$5.7K → BPTS
3$21,852$3,621.00$12,099$370.76+$9.8K → BPTS
4$27,722$4,340.18$12,870$383.63+$14.9K → BPTS
5$34,809$5,145.80$13,678$396.60+$21.1K → BPTS
6$43,284$6,038.47$14,526$409.67+$28.8K → BPTS
7$53,331$7,017.47$15,413$422.82+$37.9K → BPTS
8$65,145$8,080.76$16,343$436.05+$48.8K → BPTS
9$78,930$9,225.06$17,315$449.35+$61.6K → BPTS
10$94,901$10,445.94$18,332$462.70+$76.6K → BPTS

BPTS vs STAG: Complete Analysis 2026

BPTS — Stock

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Full BPTS Calculator →

STAG — REIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this BPTS vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPTS vs SCHDBPTS vs JEPIBPTS vs OBPTS vs KOBPTS vs MAINBPTS vs PLDBPTS vs EQRBPTS vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.